circLPAR3 increased prostate cancer cell proliferation and docetaxel resistance in CDX models. (IMAGE)
Caption
(A) Representative images of xenograft tumors in the oe-circLPAR3 22Rv1-DR group and its control group (vector) after treatment with docetaxel or DMSO. (B, C) Tumor growth curves were plotted and tumor weights were measured. (D) Immunohistochemistry assessment of Ki-67 and CHAC1 expression in the oe-circLPAR3 group and its control group. (E) METTL3/IGF2BP2-regulated circLPAR3 promotes proliferation of drug-resistant cells and confers ferroptosis resistance to docetaxel-resistant prostate cancer cells by binding to PCBP2 and inhibiting the latter’s stabilizing effect on CHAC1 mRNA. ∗∗P < 0.01 and ∗∗∗∗P < 0.0001.
Credit
Yetao Zhang, Yuxiang Dong, Kai Li, Tong Zhao, Yongshan Li, Mingyang Pang, Yong Wei, Bing Yao, Qingyi Zhu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND